Time Course of Calcium Concentrations and Risk Factors for Hypocalcemia in Patients Receiving Denosumab for the Treatment of Bone Metastases From Cancer

Hiroaki Ikesue, Toshikazu Tsuji, Koujiro Hata, Hiroyuki Watanabe, Kazuto Mishima, Mayako Uchida, Nobuaki Egashira, Toshihiro Miyamoto, Eishi Baba, Koichi Akashi, Koichi Takayama, Yoichi Nakanishi, Eriko Tokunaga, Tatsuro Okamoto, Yoshihiko Maehara, Akira Yokomizo, Seiji Naito, Makoto Kubo, Masao Tanaka, Satohiro Masuda

研究成果: ジャーナルへの寄稿記事

15 引用 (Scopus)

抄録

Background: Severe hypocalcemia sometimes develops during denosumab treatment for bone metastases from cancer and is, therefore, an important issue. However, limited information is available on the risk factors for hypocalcemia and the appropriate interval for monitoring serum calcium concentration. Objective: The present study aimed to identify the risk factors for grade ≥2 hypocalcemia and to investigate the time course of serum calcium concentrations in patients receiving denosumab for bone metastases from cancer. Method: The medical records of 66 cancer patients treated with denosumab between April 2012 and August 2013 were retrospectively reviewed. Result: Of the 66 enrolled patients, 11, 5, and 1 developed grade 1, 2, and 3 hypocalcemia, respectively. All 4 patients with a baseline estimated glomerular filtration rate (eGFR) of <30 mL/min developed hypocalcemia. Hypocalcemia occurred in only 20%, 24%, and 15% of patients with an eGFR of 30 to 59, 60 to 89, and ≥90 mL/min, respectively. Multivariate logistic regression analysis revealed that lower eGFR values (odds ratio, 1.72 per 10 mL/min decrease, P = 0.02) were significantly associated with grade ≥2 hypocalcemia. In 11 patients who developed hypocalcemia during the first treatment course, the mean calcium concentrations decreased from 9.8 mg/dL at baseline to 8.4 mg/dL during the first week and reached a nadir of 8.1 mg/dL during the second week. Conclusion: Our results support more frequent monitoring of serum calcium concentrations at baseline and during the first 2 weeks of treatment in patients receiving denosumab, especially those with an eGFR <30 mL/min.

元の言語英語
ページ(範囲)1159-1165
ページ数7
ジャーナルAnnals of Pharmacotherapy
48
発行部数9
DOI
出版物ステータス出版済み - 9 2014

Fingerprint

Hypocalcemia
Neoplasm Metastasis
Calcium
Bone and Bones
Glomerular Filtration Rate
Neoplasms
Bone Neoplasms
Therapeutics
Serum
Denosumab
Medical Records
Logistic Models
Odds Ratio
Regression Analysis

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

これを引用

Time Course of Calcium Concentrations and Risk Factors for Hypocalcemia in Patients Receiving Denosumab for the Treatment of Bone Metastases From Cancer. / Ikesue, Hiroaki; Tsuji, Toshikazu; Hata, Koujiro; Watanabe, Hiroyuki; Mishima, Kazuto; Uchida, Mayako; Egashira, Nobuaki; Miyamoto, Toshihiro; Baba, Eishi; Akashi, Koichi; Takayama, Koichi; Nakanishi, Yoichi; Tokunaga, Eriko; Okamoto, Tatsuro; Maehara, Yoshihiko; Yokomizo, Akira; Naito, Seiji; Kubo, Makoto; Tanaka, Masao; Masuda, Satohiro.

:: Annals of Pharmacotherapy, 巻 48, 番号 9, 09.2014, p. 1159-1165.

研究成果: ジャーナルへの寄稿記事

Ikesue, H, Tsuji, T, Hata, K, Watanabe, H, Mishima, K, Uchida, M, Egashira, N, Miyamoto, T, Baba, E, Akashi, K, Takayama, K, Nakanishi, Y, Tokunaga, E, Okamoto, T, Maehara, Y, Yokomizo, A, Naito, S, Kubo, M, Tanaka, M & Masuda, S 2014, 'Time Course of Calcium Concentrations and Risk Factors for Hypocalcemia in Patients Receiving Denosumab for the Treatment of Bone Metastases From Cancer', Annals of Pharmacotherapy, 巻. 48, 番号 9, pp. 1159-1165. https://doi.org/10.1177/1060028014539919
Ikesue, Hiroaki ; Tsuji, Toshikazu ; Hata, Koujiro ; Watanabe, Hiroyuki ; Mishima, Kazuto ; Uchida, Mayako ; Egashira, Nobuaki ; Miyamoto, Toshihiro ; Baba, Eishi ; Akashi, Koichi ; Takayama, Koichi ; Nakanishi, Yoichi ; Tokunaga, Eriko ; Okamoto, Tatsuro ; Maehara, Yoshihiko ; Yokomizo, Akira ; Naito, Seiji ; Kubo, Makoto ; Tanaka, Masao ; Masuda, Satohiro. / Time Course of Calcium Concentrations and Risk Factors for Hypocalcemia in Patients Receiving Denosumab for the Treatment of Bone Metastases From Cancer. :: Annals of Pharmacotherapy. 2014 ; 巻 48, 番号 9. pp. 1159-1165.
@article{a5cab702456d4298a008c5bed218779f,
title = "Time Course of Calcium Concentrations and Risk Factors for Hypocalcemia in Patients Receiving Denosumab for the Treatment of Bone Metastases From Cancer",
abstract = "Background: Severe hypocalcemia sometimes develops during denosumab treatment for bone metastases from cancer and is, therefore, an important issue. However, limited information is available on the risk factors for hypocalcemia and the appropriate interval for monitoring serum calcium concentration. Objective: The present study aimed to identify the risk factors for grade ≥2 hypocalcemia and to investigate the time course of serum calcium concentrations in patients receiving denosumab for bone metastases from cancer. Method: The medical records of 66 cancer patients treated with denosumab between April 2012 and August 2013 were retrospectively reviewed. Result: Of the 66 enrolled patients, 11, 5, and 1 developed grade 1, 2, and 3 hypocalcemia, respectively. All 4 patients with a baseline estimated glomerular filtration rate (eGFR) of <30 mL/min developed hypocalcemia. Hypocalcemia occurred in only 20{\%}, 24{\%}, and 15{\%} of patients with an eGFR of 30 to 59, 60 to 89, and ≥90 mL/min, respectively. Multivariate logistic regression analysis revealed that lower eGFR values (odds ratio, 1.72 per 10 mL/min decrease, P = 0.02) were significantly associated with grade ≥2 hypocalcemia. In 11 patients who developed hypocalcemia during the first treatment course, the mean calcium concentrations decreased from 9.8 mg/dL at baseline to 8.4 mg/dL during the first week and reached a nadir of 8.1 mg/dL during the second week. Conclusion: Our results support more frequent monitoring of serum calcium concentrations at baseline and during the first 2 weeks of treatment in patients receiving denosumab, especially those with an eGFR <30 mL/min.",
author = "Hiroaki Ikesue and Toshikazu Tsuji and Koujiro Hata and Hiroyuki Watanabe and Kazuto Mishima and Mayako Uchida and Nobuaki Egashira and Toshihiro Miyamoto and Eishi Baba and Koichi Akashi and Koichi Takayama and Yoichi Nakanishi and Eriko Tokunaga and Tatsuro Okamoto and Yoshihiko Maehara and Akira Yokomizo and Seiji Naito and Makoto Kubo and Masao Tanaka and Satohiro Masuda",
year = "2014",
month = "9",
doi = "10.1177/1060028014539919",
language = "English",
volume = "48",
pages = "1159--1165",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "9",

}

TY - JOUR

T1 - Time Course of Calcium Concentrations and Risk Factors for Hypocalcemia in Patients Receiving Denosumab for the Treatment of Bone Metastases From Cancer

AU - Ikesue, Hiroaki

AU - Tsuji, Toshikazu

AU - Hata, Koujiro

AU - Watanabe, Hiroyuki

AU - Mishima, Kazuto

AU - Uchida, Mayako

AU - Egashira, Nobuaki

AU - Miyamoto, Toshihiro

AU - Baba, Eishi

AU - Akashi, Koichi

AU - Takayama, Koichi

AU - Nakanishi, Yoichi

AU - Tokunaga, Eriko

AU - Okamoto, Tatsuro

AU - Maehara, Yoshihiko

AU - Yokomizo, Akira

AU - Naito, Seiji

AU - Kubo, Makoto

AU - Tanaka, Masao

AU - Masuda, Satohiro

PY - 2014/9

Y1 - 2014/9

N2 - Background: Severe hypocalcemia sometimes develops during denosumab treatment for bone metastases from cancer and is, therefore, an important issue. However, limited information is available on the risk factors for hypocalcemia and the appropriate interval for monitoring serum calcium concentration. Objective: The present study aimed to identify the risk factors for grade ≥2 hypocalcemia and to investigate the time course of serum calcium concentrations in patients receiving denosumab for bone metastases from cancer. Method: The medical records of 66 cancer patients treated with denosumab between April 2012 and August 2013 were retrospectively reviewed. Result: Of the 66 enrolled patients, 11, 5, and 1 developed grade 1, 2, and 3 hypocalcemia, respectively. All 4 patients with a baseline estimated glomerular filtration rate (eGFR) of <30 mL/min developed hypocalcemia. Hypocalcemia occurred in only 20%, 24%, and 15% of patients with an eGFR of 30 to 59, 60 to 89, and ≥90 mL/min, respectively. Multivariate logistic regression analysis revealed that lower eGFR values (odds ratio, 1.72 per 10 mL/min decrease, P = 0.02) were significantly associated with grade ≥2 hypocalcemia. In 11 patients who developed hypocalcemia during the first treatment course, the mean calcium concentrations decreased from 9.8 mg/dL at baseline to 8.4 mg/dL during the first week and reached a nadir of 8.1 mg/dL during the second week. Conclusion: Our results support more frequent monitoring of serum calcium concentrations at baseline and during the first 2 weeks of treatment in patients receiving denosumab, especially those with an eGFR <30 mL/min.

AB - Background: Severe hypocalcemia sometimes develops during denosumab treatment for bone metastases from cancer and is, therefore, an important issue. However, limited information is available on the risk factors for hypocalcemia and the appropriate interval for monitoring serum calcium concentration. Objective: The present study aimed to identify the risk factors for grade ≥2 hypocalcemia and to investigate the time course of serum calcium concentrations in patients receiving denosumab for bone metastases from cancer. Method: The medical records of 66 cancer patients treated with denosumab between April 2012 and August 2013 were retrospectively reviewed. Result: Of the 66 enrolled patients, 11, 5, and 1 developed grade 1, 2, and 3 hypocalcemia, respectively. All 4 patients with a baseline estimated glomerular filtration rate (eGFR) of <30 mL/min developed hypocalcemia. Hypocalcemia occurred in only 20%, 24%, and 15% of patients with an eGFR of 30 to 59, 60 to 89, and ≥90 mL/min, respectively. Multivariate logistic regression analysis revealed that lower eGFR values (odds ratio, 1.72 per 10 mL/min decrease, P = 0.02) were significantly associated with grade ≥2 hypocalcemia. In 11 patients who developed hypocalcemia during the first treatment course, the mean calcium concentrations decreased from 9.8 mg/dL at baseline to 8.4 mg/dL during the first week and reached a nadir of 8.1 mg/dL during the second week. Conclusion: Our results support more frequent monitoring of serum calcium concentrations at baseline and during the first 2 weeks of treatment in patients receiving denosumab, especially those with an eGFR <30 mL/min.

UR - http://www.scopus.com/inward/record.url?scp=84905449426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905449426&partnerID=8YFLogxK

U2 - 10.1177/1060028014539919

DO - 10.1177/1060028014539919

M3 - Article

AN - SCOPUS:84905449426

VL - 48

SP - 1159

EP - 1165

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 9

ER -